Menu

Studies Retracted After UCLA Investigation

Most of the authors have had papers pulled in the past.

Jul 21, 2017
Diana Kwon

PIXABAY, JACKMAC34A 2011 Cancer Research paper was retracted earlier this month (July 2) after an investigation by the University of California, Los Angeles (UCLA). The work was conducted by a group of cancer investigators at the university, including James Economou, the former vice chancellor for research.

According to the retraction report, the request came from UCLA, where an institutional review found that one of the paper’s figures duplicated aspects of another paper.

“This is the second retraction we’re aware of to come out of an investigation by UCLA’s Office of Research Policy and Compliance that has touched this group of scientists,” Retraction Watch reports. A 2012 Molecular Cancer Therapeutics paper coauthored by Economou was retracted in May.

This is the fourth retraction for one of the study’s coauthors, Benjamin Bonavida, a retired UCLA scientist. When asked about the most recent Cancer Research study, he tells Retraction Watch that “all the work was done in Economou’s lab, not mine. I have no idea what exactly took place.”

Only one of the coauthors of the Cancer Research paper has no previous retractions.

Retractions of scientific papers are on the rise. Just last year, more than 650 papers were pulled for various reasons, ranging from image duplication to fraud.

See “Infographic: Web of Retractions

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.